Diminished levels of nasal S100A7 (psoriasin) in seasonal allergic rhinitis: an effect mediated by Th2 cytokines

Respiratory Research

Lars-Olaf Cardell³  Mikael Benson¹  Rolf Uddman²  Mia Eriksson³  Malin Järnkrants³  Camilla Rydberg³  Anne Månsson Kvarnhammar³ 

[1] Department of Pediatrics, Linköping University Hospital, Linköping, Sweden;Laboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology, Skåne University Hospital, Malmö, Sweden;Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Huddinge, Sweden

关键词: Th2 cytokines;    seasonal allergic rhinitis;    lipopolysaccharide;    epithelium;    antimicrobial peptide;    allergen-specific immunotherapy;   

Others  :  796759
DOI  :  10.1186/1465-9921-13-2

 received in 2011-10-03, accepted in 2012-01-09,  发布年份 2012

【 摘 要 】

Background

S100A7 is an antimicrobial peptide involved in several inflammatory diseases. The aim of the present study was to explore the expression and regulation of S100A7 in seasonal allergic rhinitis (SAR).

Methods

Nasal lavage (NAL) fluid was obtained from healthy controls before and after lipopolysaccharide (LPS) provocation, from SAR patients before and after allergen challenge, and from SAR patients having completed allergen-specific immunotherapy (ASIT). Nasal biopsies, nasal epithelial cells and blood were acquired from healthy donors. The airway epithelial cell line FaDu was used for in vitro experiments. Real-time RT-PCR and immunohistochemistry were used to determine S100A7 expression in nasal tissue and cells. Release of S100A7 in NAL and culture supernatants was measured by ELISA. The function of recombinant S100A7 was explored in epithelial cells, neutrophils and peripheral blood mononuclear cells (PBMC).

Results

Nasal administration of LPS induced S100A7 release in healthy non-allergic subjects. The level of S100A7 was lower in NAL from SAR patients than from healthy controls, and it was further reduced in the SAR group 6 h post allergen provocation. In contrast, ASIT patients displayed higher levels after completed treatment. S100A7 was expressed in the nasal epithelium and in glands, and it was secreted by cultured epithelial cells. Stimulation with IL-4 and histamine repressed the epithelial S100A7 release. Further, recombinant S100A7 induced activation of neutrophils and PBMC.

Conclusions

The present study shows an epithelial expression and excretion of S100A7 in the nose after microbial stimulation. The levels are diminished in rhinitis patients and in the presence of an allergic cytokine milieu, suggesting that the antimicrobial defense is compromised in patients with SAR.

【 授权许可】

   
2012 Kvarnhammar et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322(4):1111-1122.
• [2]Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B, et al.: Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J Invest Dermatol 1991, 97(4):701-712.
• [3]West NR, Watson PH: S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 2010, 29(14):2083-2092.
• [4]Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008, 63(4):352-359.
• [5]Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L: Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007, 27(5A):3051-3058.
• [6]Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Glaser R: Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 2007, 133(4):253-261.
• [7]Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM: Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2005, 6(1):57-64.
• [8]Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B, Etzerodt M, Honore B, Celis JE, Thestrup-Pedersen K: Psoriasin: a novel chemotactic protein. J Invest Dermatol 1996, 107(1):5-10.
• [9]Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B, et al.: Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008, 181(2):1499-1506.
• [10]Zheng Y, Niyonsaba F, Ushio H, Ikeda S, Nagaoka I, Okumura K, Ogawa H: Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation. Immunology 2008, 124(3):357-367.
• [11]Bryborn M, Adner M, Cardell LO: Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and non-allergic individuals using 2-dimensional gel electrophoresis and mass spectrometry. Respir Res 2005, 6:118. BioMed Central Full Text
• [12]Bryborn M, Mansson A, Cardell LO, Adner M: Differentiated S100A7 expression in infected tonsils and tonsils from allergic individuals. FEMS Immunol Med Microbiol 2008, 53(3):413-420.
• [13]Bryborn M, Hallden C, Sall T, Adner M, Cardell LO: Comprehensive evaluation of genetic variation in S100A7 suggests an association with the occurrence of allergic rhinitis. Respir Res 2008, 9:29. BioMed Central Full Text
• [14]Tieu DD, Peters AT, Carter RT, Suh L, Conley DB, Chandra R, Norton J, Grammer LC, Harris KE, Kato A, et al.: Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis. J Allergy Clin Immunol 2010, 125(3):667-675.
• [15]Richer SL, Truong-Tran AQ, Conley DB, Carter R, Vermylen D, Grammer LC, Peters AT, Chandra RK, Harris KE, Kern RC, et al.: Epithelial genes in chronic rhinosinusitis with and without nasal polyps. Am J Rhinol 2008, 22(3):228-234.
• [16]Mansson A, Bachar O, Adner M, Cardell LO: Nasal CpG oligodeoxynucleotide administration induces a local inflammatory response in nonallergic individuals. Allergy 2009, 64(9):1292-1300.
• [17]Ekman AK, Fransson M, Rydberg C, Adner M, Cardell LO: Nasal Challenge with LPS Stimulates the Release of Macrophage Inflammatory Protein 1alpha. Int Arch Allergy Immunol 2009, 149(2):154-160.
• [18]Benson M, Strannegard IL, Wennergren G, Strannegard O: Interleukin-5 and interleukin-8 in relation to eosinophils and neutrophils in nasal fluids from school children with seasonal allergic rhinitis. Pediatr Allergy Immunol 1999, 10(3):178-185.
• [19]Rydberg C, Mansson A, Uddman R, Riesbeck K, Cardell LO: Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 2009, 128(1 Suppl):e600-611.
• [20]Bogefors J, Rydberg C, Uddman R, Fransson M, Mansson A, Benson M, Adner M, Cardell LO: Nod1, Nod2 and Nalp3 receptors, new potential targets in treatment of allergic rhinitis? Allergy 2010, 65(10):1222-1226.
• [21]Mansson A, Cardell LO: Role of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils. J Leukoc Biol 2009, 85(4):719-727.
• [22]Mansson A, Adner M, Hockerfelt U, Cardell LO: A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology 2006, 118(4):539-548.
• [23]Mansson A, Adner M, Cardell LO: Toll-like receptors in cellular subsets of human tonsil T cells: altered expression during recurrent tonsillitis. Respir Res 2006, 7:36. BioMed Central Full Text
• [24]Kinhult J, Adner M, Uddman R, Cardell LO: Pituitary adenylate cyclase-activating polypeptide, effects in the human nose. Clin Exp Allergy 2003, 33(7):942-949.
• [25]Glaser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, Kobliakova J, Folster-Holst R, Proksch E, Schroder JM, Schwarz T: The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol 2009, 129(3):641-649.
• [26]Sugiura H, Ebise H, Tazawa T, Tanaka K, Sugiura Y, Uehara M, Kikuchi K, Kimura T: Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br J Dermatol 2005, 152(1):146-149.
• [27]Harder J, Dressel S, Wittersheim M, Cordes J, Meyer-Hoffert U, Mrowietz U, Folster-Holst R, Proksch E, Schroder JM, Schwarz T, et al.: Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol 2010, 130(5):1355-1364.
• [28]Tieu DD, Kern RC, Schleimer RP: Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. J Allergy Clin Immunol 2009, 124(1):37-42.
• [29]Canonica GW, Compalati E: Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009, 158(3):260-271.
• [30]Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, Ciprandi G: Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 105(1 Pt 1):54-57.
• [31]Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A: Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax 2005, 60(1):17-21.
• [32]Micillo E, Bianco A, D'Auria D, Mazzarella G, Abbate GF: Respiratory infections and asthma. Allergy 2000, 55(Suppl 61):42-45.
• [33]Sykes A, Johnston SL: Etiology of asthma exacerbations. J Allergy Clin Immunol 2008, 122(4):685-688.
• [34]Newcomb DC, Peebles RS Jr: Bugs and asthma: a different disease? Proc Am Thorac Soc 2009, 6(3):266-271.
• [35]Lauriello M, Muzi P, Di Rienzo L, Di Stanislao C, Tirelli GC, Bologna M: A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol Ital 2005, 25(5):284-291.
• [36]Reithmayer K, Meyer KC, Kleditzsch P, Tiede S, Uppalapati SK, Glaser R, Harder J, Schroder JM, Paus R: Human hair follicle epithelium has an antimicrobial defence system that includes the inducible antimicrobial peptide psoriasin (S100A7) and RNase 7. Br J Dermatol 2009, 161(1):78-89.
• [37]Benson M, Strannegard IL, Wennergren G, Strannegard O: Cytokines in nasal fluids from school children with seasonal allergic rhinitis. Pediatr Allergy Immunol 1997, 8(3):143-149.
• [38]Erin EM, Zacharasiewicz AS, Nicholson GC, Tan AJ, Higgins LA, Williams TJ, Murdoch RD, Durham SR, Barnes PJ, Hansel TT: Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005, 35(12):1608-1614.
• [39]Kosa L, Kovacs N, Halasz A: Interleukines in nasal lavage. Allergy 2002, 57(1):63-64.